OAV101
COAV101B12302
Phase 3 gene_therapy completed
Quick answer
OAV101 for Spinal Muscular Atrophy is a Phase 3 program (gene_therapy) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Spinal Muscular Atrophy
- Phase
- Phase 3
- Modality
- gene_therapy
- Status
- completed